Headlands Research has acquired a Massachusetts–based clinical research site specialised in neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

The Headlands Research Eastern Massachusetts site is set to deepen the neurology research capabilities of the expanding network of multinational trial sites.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

With a focus on diversity, quality, and advanced technology, the site aims to improve the lives of people through new medical therapies.

Headlands Research CEO Cathy Collins said: “With its longstanding focus on memory and movement disorders, Headlands Research Eastern Massachusetts strengthens the breadth and depth of our existing neurology speciality research.

“We are proud to welcome Headlands Research Eastern Massachusetts to our expanding network of clinical trial sites, helping to make clinical trials and the innovative therapies they provide accessible to more people.”

The research site is led by founder and principal investigator Dr. Donald Marks.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Marks currently serves at Beth Israel Deaconess Hospital – Plymouth, as a staff in neurology division.

Marks has expertise in the diagnosis and treatment of Alzheimer’s disease, Parkinson’s disease, and related disorders.

Marks said: “My team and I are proud of our ability to provide compassionate care for patients and families facing the impact of neurodegenerative diseases.

“Through our research, we can help fill the gap in the availability of disease-modifying treatments and effective long-term symptomatic therapies.

“Joining Headlands Research increases the number of clinical trials and innovative, investigational treatments available for our patient population.”

The company is also planning to expand its network of clinical trial sites throughout the year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact